NEW ORLEANS, Louisiana, June 6, 2026
New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have highlighted the potential of berobenatide, an investigational ultra-long-acting GLP-1 receptor agonist (GLP-1 RA), to transform obesity and type 2 diabetes management through less frequent dosing while maintaining robust weight-loss efficacy. Findings from the Phase 2b VESPER clinical program demonstrated that berobenatide achieved significant weight reduction in individuals living with overweight or obesity, including those with and without type 2 diabetes, while supporting a promising safety and tolerability profile. Researchers believe the therapy could represent a next-generation advancement in chronic weight management by enabling once-monthly administration, a significant departure from currently available weekly injectable treatments. As obesity and type 2 diabetes continue to place substantial burdens on healthcare systems worldwide, innovative therapies capable of improving adherence, convenience, and long-term outcomes remain a major focus of clinical development.
VESPER-3 Data Highlight Potential for Once-Monthly Weight Management
The most anticipated findings came from the VESPER-3 Phase 2b trial, which evaluated whether berobenatide could successfully transition from weekly administration to a once-monthly dosing schedule while preserving efficacy and tolerability. The study enrolled adults with overweight or obesity who did not have type 2 diabetes and assessed treatment outcomes over a 28-week period. Results demonstrated that berobenatide achieved placebo-adjusted weight loss of up to 12.3% at the 4.8 mg monthly dose, supporting the feasibility of extended dosing intervals for chronic weight management. Safety findings were consistent with the established GLP-1 receptor agonist class, with favorable tolerability observed throughout treatment.
Investigators emphasized that reducing injection frequency could significantly lessen treatment burden for patients requiring long-term therapy while potentially improving adherence and persistence. The final endpoint analysis for VESPER-3 will be conducted at 64 weeks, providing valuable long-term data regarding efficacy, durability of weight loss, and safety.
Positive Results Extend Across Obesity and Type 2 Diabetes Populations
Advertisement
Additional findings from the VESPER-1 and VESPER-2 Phase 2b studies reinforced the broad therapeutic potential of berobenatide across diverse patient populations. VESPER-1 evaluated once-weekly berobenatide in adults with obesity and demonstrated meaningful weight reduction alongside a favorable tolerability profile. An open-label extension further supported efficacy at higher doses and alternative dosing schedules. Meanwhile, the VESPER-2 trial extended these encouraging outcomes to individuals living with overweight or obesity in addition to type 2 diabetes, demonstrating an attractive risk-benefit profile and highlighting the therapy’s potential to address both body weight and metabolic health.
Researchers noted that the ability to support clinically meaningful weight reduction while also helping regulate blood glucose could make berobenatide particularly valuable for patients facing the dual challenges of obesity and diabetes. Given the growing prevalence of metabolic disease worldwide, therapies capable of addressing multiple cardiometabolic risk factors remain highly sought after by clinicians and healthcare systems.
Ultra-Long-Acting GLP-1 Innovation Advances Toward Phase 3 Development
Berobenatide was specifically engineered as an ultra-long-acting GLP-1 receptor agonist designed to regulate appetite, support weight loss, and improve glycemic control while offering significantly greater dosing flexibility than conventional therapies. Investigators stated that results from VESPER-1, VESPER-2, and VESPER-3 have provided important guidance for the design of upcoming VESPER-4 and VESPER-6 Phase 3 clinical trials, which are expected to further evaluate efficacy and safety in larger patient populations.
The prospect of monthly administration has generated significant interest among obesity specialists, endocrinologists, and primary care providers seeking treatment options that reduce injection burden without compromising outcomes. As the obesity therapeutics market continues to evolve rapidly, berobenatide’s combination of substantial weight loss, favorable tolerability, metabolic benefits, and the potential for once-monthly dosing positions it among the most promising next-generation GLP-1 therapies currently in clinical development. If future studies confirm these results, the therapy could represent a major advancement in long-term obesity and diabetes management.
Source: American Diabetes Association press release
